Novel Monoclonal Antibody Therapy Meeting the Needs of Non-Small Cell Lung Cancer Patients

Release Date: 15-Nov-2020

Researchers have bene trying to evaluate the primary end point of overall survival (OS) with tislelizumab compared with docetaxel as an effective treatment of patients with locally advanced or metastatic nonandndash;small cell lung cancer (NSCLC) who have been receiving platinum-based chemotherapy. As per the research study, the monoclonal antibody safety profile was studied with respect to the patients who have been waiting for too long for an efficient therapy. The drug getting evaluated in the clinical research study is estimated to be effective against wide types of cancer and it is estimated that the drug’s clinical outcomes will make it approved for the regulatory filings in China and globally.

The respective clinical research study is an open-label study which included patients suffering from advanced non-small cell lung cancer. Some of the secondary aims of the clinical research study was to study about include objective response rate, duration of response, progression-free survival, and safety. Total of 805 patients were enrolled in the study and the patients enrolled in the study have been randomized 2:1 to receive either tislelizumab or docetaxel across 10 different countries.

In the current time, the drug Tislelizumab is under verification as a monotherapy or combination therapy with some of the other available treatments against different types of solid cancers such as hematologic malignancies. Already the China National Medical Products Administration has approved the drug as an efficient therapy for the treatment of the patients suffering from locally advanced or metastatic urothelial carcinoma with high PD-L1 expression. Although the therapy is not currently approved in the US but the future clinical outcome expected from the drug has delivered tons of hopes to the patients and the researchers in the US.